Lipid-Lowering Treatment in Hypercholesterolemic Patients: The CEPHEUS Thailand Survey

Journal of the Medical Association of Thailand

Volumn 94, Issue 12, 2011, Pages 1424-1434

  Sukonthasarn, Apichard ^a   Homsanit, Mayuree ^b   Prommete, Bundit ^b   Chotinaiwattarakul, Chunhakasem ^b   Piamsomboon, Chumpol ^c   Likittanasombat, Khanchit ^d  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

LDL goal; Lipid lowering treatment

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AWARENESS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; GOAL ATTAINMENT; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MALE; MEDICAL INFORMATION; METABOLIC SYNDROME X; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREDICTION; PROFESSIONAL COMPETENCE; PROFESSIONAL PRACTICE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THAILAND;

EID: 84857080062     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Health Information Unit, Bureau of Health Policy and Strategy, Ministry of Public Health of Thailand. Public health statistics [Internet]. 2007-2009 [cited 2011 Mar 16]. Available from: http://bps.ops.moph.go.th/Healthinformation/
2. Health Information Unit, Bureau of Health Policy and Strategy, Ministry of Public Health of Thailand. Public health statistics [Internet]. 2005-2009 [cited 2011 Mar 16]. Available from: http://bps.ops.moph.go.th/Statistic/2.3.4-52.pdf
3. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72.
4. Rosenson RS. Statins: can the new generation make an impression? Expert Opin Emerg Drugs 2004; 9: 269-79.
5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
8. Nitiyanant W, Sritara P, Deerochanawong C, Ngarmukos P, Koanantakul B. Lipid treatment assessment project II in Thailand (LTAP-II Thailand). J Med Assoc Thai 2008; 91: 836-45.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
10. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120: 28-34.
11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17: 530-40.
12. Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin 2008; 24: 1951-63.
13. Stein EA, Black DM. Lipoprotein changes with statins. Curr Atheroscler Rep 2002; 4: 14-8.
14. Mammas IN, Bertsias GK, Linardakis M, Tzanakis NE, Labadarios DN, Kafatos AG. Cigarette smoking, alcohol consumption, and serum lipid profile among medical students in Greece. Eur J Public Health 2003; 13: 278-82.
15. Meenakshisundaram R, Rajendiran C, Thirumalaikolundusubramanian P. Lipid and lipoprotein profiles among middle aged male smokers: a study from southern India. Tob Induc Dis 2010; 8: 11.
16. Campbell SC, Moffatt RJ, Stamford BA. Smoking and smoking cessation-the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008; 201: 225-35.
17. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50-III57.
18. Park JE, Chiang CE, Munawar M, Pham GK, Sukonthasarn A, Aquino AR, et al. Lipidlowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Cardiovasc Prev Rehabil 2011 Mar 7. doi: 10.1177/ 1741826710397100